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To the Editor: Randomized controlled trials have shown that the phosphodiesterase-4 48 
inhibitor Apremilast is an effective and safe option in the treatment of psoriasis and 49 
psoriatic arthritis (PsA) (1) with real-world data now emerging from the dermatology and 50 
rheumatology settings (2-5). The Canadian multicenter retrospective study showed no 51 
increased reported AEs when Apremilast was used in monotherapy (MT) or in combination 52 
therapy (CT) with systemic drugs in patients with plaque psoriasis and that the CT group did 53 
not have superior efficacy, likely reflecting more resistant disease (2). Such data is still 54 
sparse from the real-world experience in PsA patients. 55 
In the first real-life report of Apremilast 30mg BD in active PsA, data were retrospectively 56 
reviewed in seventy-one patients with active PsA at the tertiary Leeds Psoriatic Service (4).  57 
Herein we report a sub-analysis of the safety and response to therapy data according to the 58 
treatment regimen.The proportions and means were compared using Fisher’s exact test and 59 
two-tailed unpaired-t-test respectively. Statistical analysis was performed with GraphPad 60 
Prism 7 with p≤0.05 considered significant.  61 
Clinical characteristics and AEs are reported in table 1 and table 2 respectively. Of 71 PsA 62 
patients,  39 (54.9%) were on MT, 32 (45.1%) on CT (Table 1). Sub-analysis of the two groups 63 
showed no increased number of the reported AEs when Apremilast was used in MT or in CT 64 
with conventional and/or biological disease modifying antirheumatic drugs (DMARDS) (table 65 
2), confirming Ighani et al. results (2). We did not perform a statistical analysis due to the 66 
small number of AEs. Unlike RCTs (1) and the retrospective study of Ighani et al (2), 67 
unwanted weight loss and upper respiratory tract infections were not reported in our 68 
experience (table 2) (4). Of the 51 patients with a mean follow-up ≥6 months, in which we 69 
could assess the response to therapy (4), 28 were on MT and 23 were taking Apremilast in 70 
combination with conventional (n=16) or biologic (n=5) DMARDs, or with both (n=2). 71 
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According to the response criteria (4), a slightly greater proportion of MT patients achieved 72 
response (18/28 vs 13/23, 64.3% vs 56.5%), with not significant difference. As in the plaque 73 
psoriasis real-world experience (2), this may be explained by more difficult-to-treat PsA 74 
cases requiring additional drugs in order to control disease activity. When comparing 75 
number of previous DMARDs and disease duration, there was no difference between MT 76 
and CT groups (p>0.05). 77 
In conclusion, the favourable safety profile of Apremilast either in MT or CT makes it highly 78 
desirable in some clinical scenarios. While MT could serve to control chronically active 79 
disease not responsive to previous conventional/biologic DMARDS or to treat earlier on 80 
patients with less severe joint/skin manifestations who may not yet require a biologic 81 
DMARD (4), the CT may reduce disease activity not adequately controlled with other 82 
treatments without increasing risk of AEs. In clinical practice use of CT, particularly with 83 
biologics, is currently limited by costs. Larger observational data are needed to define cases 84 
who may benefit of MT and/or CT and characterise specific AEs . 85 
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Table Legend 119 
Table 1. Proportions were compared by using the Fisher’s exact test. Means were compared 120 
using a two-tailed unpaired t test.  SD, Standard deviation. 121 
Table 1. “Clinical characteristics and treatment regimen of the 71 PsA patients on 122 
Apremilast ” 123 
Table 2. Mean numbers of reported AEs per subject were compared by using a two-tailed 124 
unpaired t test. AE, Adverse event; SD, standard deviation. 125 
Table 2. “Reported adverse events (AEs) in PsA patients treated with Apremilast  126 
in real-world setting” 127 
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Table 1. Clinical characteristics and treatment regimen of the 71 PsA patients on 
Apremilast   
 Monotherapy 
39 (54.9) 
Combination Therapy 
32 (45.1) 
P 
Male, n (%) 16 (41.3) 17 (53.1) 0.3 
Age, years, mean (SD) 50.5 (2.3) 51.5 (2) 0.7 
Disease duration, years, mean (SD) 7.1 (6.3) 8.5 (6.6) 0.3 
Psoriasis, n (%) 33 (84.6) 26 (81.3) 0.8 
Time of follow-up, days, mean (SD) 182.5 (114.1) 160.5 (94.3) 0.4 
Number of failed cDMARDs prior to 
Apremilast, mean (SD) 
1.6 (1) 1.1 (1.1) 0.2 
Number of failed bDMARDs prior to 
Apremilast, mean (SD) 
1.2 (1.4) 1.6 (1.6) 0.4 
Failed DMARDs  
prior to Apremilast, n (%) 
   
Methotrexate 31 (79.5) 20 (62.5) 0.2 
Sulfasalazine 22 (56.4) 3 (9.4) <0.0001 
Hydroxychloroquine 7 (18) 5 (15.6) >0.9 
Leflunomide 6 (15.4) 1 (3.1) 0.06 
Cyclosporine 5 (12.8) 0 (0) 0.06 
Certolizumab 
Golimumab 
Ustekinumab 
Adalimumab 
Etanercept 
Infliximab 
Secukinumab 
Tocilizumab 
0 (0) 
3 (7.7) 
2 (5.1) 
13 (33.3) 
15 (38.5) 
5 (12.8) 
0 (0) 
1 (2.6) 
3 (9.4) 
6 (18.8) 
3 (9.4) 
17 (53.1) 
11 (34.4) 
6 (18.8) 
0 (0) 
0 (0) 
0.09 
0.3 
0.7 
0.1 
0.8 
0.5 
- 
- 
Prior conventional DMARDs, patients, 38 (97.4) 29 (90.6) 0.3 
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n (%) 
Prior biological DMARDs,  
patients, n (%) 
20 (51.3) 20 (70.7) 0.1 
Combination Therapy (CT), n (%)  32 (45.1)  
Dual CT  28 (39.4)  
Methotrexate - 16 (22.5) - 
Sulfasalazine - 1 (1.4) - 
Hydroxychloroquine - 2 (2.8) - 
Leflunomide - 1 (1.4) - 
Certolizumab 
Golimumab 
Ustekinumab 
Adalimumab 
Etanercept 
Secukinumab 
Tocilizumab 
- 
- 
- 
- 
- 
- 
- 
1 (1.4) 
2 (2.8) 
1 (1.4) 
1 (1.4) 
1 (1.4) 
1 (1.4) 
1 (1.4) 
- 
- 
- 
- 
- 
- 
- 
Triple CT  4 (5.6) - 
Methotrexate + Sulfasalazine - 1 (1.4) - 
Methotrexate+ Hydroxychloroquine - 1 (1.4) - 
Methotrexate + Certolizumab - 1 (1.4) - 
Methotrexate + Ustekinumab - 1 (1.4) - 
 143 
 144 
 145 
 146 
 147 
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Table 2. Reported adverse events (AEs) in PsA patients treated with Apremilast  
in real-world setting 
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Reported AEs, n (%) Monotherapy 
 
(n=39) 
Combination 
therapy 
(n=32) 
All  
 
(n=71) 
P 
Diarrhea 8 (20.5) 5 (15.6) 13 (18.3) - 
Nausea ͒  7 (18) 2 (6.3) 9 (12.7) - 
Headache 6 (15.4) 2 (6.3) 8 (11.3) - 
Vomiting  2 (5.1) 1 (3) 3 (4.2) - 
General malaise 2 (5.1) 0 (0) 2 (2.8) - 
Depression 2 (5.1) 0 (0) 2 (2.8) - 
Suicidal ideation 1 (2.6) 0 (0) 1 (1.4) - 
Abdominal pain and/or 
loss of appetite 
1 (2.6) 0 (0) 1 (1.4) - 
Reported AEs per 
subject, n (%)  
   - 
0 22 (56.4) 22 (68.8) 44 (62) - 
1 5 (12.8) 5 (15.6) 10 (14.1) - 
2 5 (12.8) 3 (9.4) 8 (11.3) - 
3 4 (10.3) 2 (6.3) 6 (8.5) - 
≥4 3 (7.7) 0 (0) 3 (4.2) - 
Number of reported AEs 
per subject, mean (SD) 
2.3 (1.1) 1.7 (0.8) 2.1 (1) 0.15 
 149 
